<DrugInformationSummary id="CDR0000790532"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about rituximab and hyaluronidase human
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.
  </DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/rituximabandhyaluronidasehuman">Rituximab and Hyaluronidase Human</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000789585">rituximab and hyaluronidase human</TerminologyLink><GlossaryLink ref="CDR0000789667">rituximab and hyaluronidase</GlossaryLink><USBrandNames><USBrandName>Rituxan Hycela</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>rih-TUK-sih-mab â€¦ HY-al-yoo-RAH-nih-days</TermPronunciation><MediaLink ref="CDR0000791482" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000791483" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e5b7e82-f018-4eaf-ae78-d6145a906b20&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Rituximab and Hyaluronidase Human</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e5b7e82-f018-4eaf-ae78-d6145a906b20&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Rituximab and hyaluronidase human is approved to be used alone or with other <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef> to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000044846" dictionary="Cancer.gov" audience="Patient">Chronic lymphocytic leukemia</GlossaryTermRef></Strong> (CLL) in adults. It is used with <GlossaryTermRef href="CDR0000613209" dictionary="Cancer.gov" audience="Patient">fludarabine phosphate</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045253" dictionary="Cancer.gov" audience="Patient">cyclophosphamide</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000428286" dictionary="Cancer.gov" audience="Patient">Diffuse large B-cell lymphoma</GlossaryTermRef>.</Strong> It is used with <GlossaryTermRef href="CDR0000044916" dictionary="Cancer.gov" audience="Patient">anthracycline</GlossaryTermRef> chemotherapy in adults whose disease has not been treated.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000428287" dictionary="Cancer.gov" audience="Patient">Follicular lymphoma</GlossaryTermRef>.</Strong> It is used in adults with follicular lymphoma that:<ItemizedList Style="bullet" id="_4"><ListItem>Has <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapsed</GlossaryTermRef> or is <GlossaryTermRef href="CDR0000045863" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> (does not <GlossaryTermRef href="CDR0000044085" dictionary="Cancer.gov" audience="Patient">respond</GlossaryTermRef> to treatment).</ListItem><ListItem>Has not been treated.</ListItem><ListItem>Has responded to <GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">rituximab</GlossaryTermRef> given together with <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef>.</ListItem><ListItem>Has not <GlossaryTermRef href="CDR0000044078" dictionary="Cancer.gov" audience="Patient">progressed</GlossaryTermRef> after treatment with chemotherapy.</ListItem></ItemizedList></ListItem>
   
   </ItemizedList>
  <Para id="_5">Rituximab and hyaluronidase human is a form of rituximab that is given as a <GlossaryTermRef href="CDR0000045914" dictionary="Cancer.gov" audience="Patient">subcutaneous</GlossaryTermRef> <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injection</GlossaryTermRef>.  This form can be given in less time  than rituximab, which is given as an <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>. The subcutaneous form is used only after patients have received one full dose of rituximab by infusion. For more information about rituximab that may apply to rituximab and hyaluronidase human, see the Drug Information Summary for <DrugRef href="CDR0000495778" url="/about-cancer/treatment/drugs/rituximab">Rituximab</DrugRef>.</Para>
 </Section><Section id="_About"><Title>More About Rituximab and Hyaluronidase Human</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/789585">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.27">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a607038.html">Rituximab and Hyaluronidase Human</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.28"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.29">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Cancer Therapies</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C136821">Find Clinical Trials for Rituximab And Hyaluronidase Human</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2017-09-01</DateFirstPublished><DateLastModified>2020-07-15</DateLastModified></DrugInformationSummary>
